Evaluate the Possible Efficacy and Safety of Empagliflozin in Patient With Ulcerative Colitis

Launched by TANTA UNIVERSITY · Nov 3, 2022

Keywords

ClinConnect Summary

This clinical trial is studying a medication called empagliflozin to see if it can help improve symptoms in patients with mild to moderate ulcerative colitis (UC). Ulcerative colitis is a condition that causes inflammation and ulcers in the lining of the digestive tract. The trial aims to determine how effective empagliflozin is at helping patients feel better and manage their condition.

To participate in the trial, you would need to be diagnosed with mild to moderate ulcerative colitis based on specific medical tests. The trial is open to adults aged 18 to 80, regardless of gender. However, certain people cannot join, such as those with other inflammatory bowel diseases, severe kidney problems, or serious allergies to empagliflozin. If you take part, you can expect to receive either the medication or a placebo (a non-active treatment) and will be monitored closely for any changes in your condition. This study is currently in the planning stages and has not started recruiting participants yet.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • •Patients with mild to moderate UC are diagnosed by history, clinical signs according to the Montreal classification of severity of ulcerative colitis and( Endoscopy, and biopsy) to establish the chronicity of inflammation and to exclude other causes of colitis.
• Exclusion Criteria:
• • Other inflammatory bowel diseases (CD).
• • History of serious hypersensitivity to empagliflozin or any component of the formulation.
• • Patients on dialysis.
• • Severe renal impairment (eGFR \<20 ml/minute/1.73m2) .
• • Chronic urinary tract infection.
• • Chronic genital infection.